BROWN GREGORY B 4

What Happened
Gregory B. Brown, a director of Aquestive Therapeutics, was granted derivative securities (options) to acquire 50,500 shares on June 10, 2026. The grant shows a $0.00 acquisition price at issue (no cash paid at grant) and is reported as a derivative award rather than an open‑market purchase or sale.

Key Details

• Transaction date: June 10, 2026; Form 4 filed June 12, 2026 (filed within the typical two-business‑day window).
• Transaction type/code: Grant / Award (derivative; code A).
• Amount: 50,500 options/derivative shares; reported price $0.00 at grant.
• Vesting: 100% of the underlying shares vest on June 10, 2027, subject to Dr. Brown’s continued service (per footnote).
• Shares owned after transaction: Not reported on the provided filing.
• No immediate sale or exercise reported.

Context
This is a compensation grant to a director (not an open‑market purchase or sale). For retail investors: such awards are common for executive and director compensation and do not by themselves indicate a buy or sell sentiment. The award vests only if Dr. Brown remains with the company through June 10, 2027.